FRG1HP: A Potential Drug Target and Biomarker (G100132352)

Target Name: FRG1HP

NCBI ID: G100132352

FRG1HP

Other Name(s): FRG1HP variant 1 | FSHD region gene 1 family member H, pseudogene | FSHD region gene 1 family member H, pseudogene, transcript variant 1

FRG1HP: A Potential Drug Target and Biomarker

Focal RNA Fragment Generation (FRG) is a technique used to generate short RNA fragments for RNA sequencing (RNA-seq) and other applications.FRG1HP is a specific FRG gene that has been identified as a potential drug target and biomarker. In this article, we will explore the FRG1HP gene, its potential drug target properties, and its potential as a biomarker for various diseases.

The FRG1HP gene

FRG1HP is a gene located on chromosome 6p12.3 and encodes for a protein known as FRG1HP.FRG1HP is a 23.5 kDa protein that is expressed in various tissues and organs, including brain, heart, liver, and muscle.FRG1HP has been shown to play a role in cell signaling pathways, including the regulation of cell adhesion, migration, and invasion.

FRG1HP as a potential drug target

FRG1HP has been identified as a potential drug target due to its involvement in various cellular processes that are associated with disease. One of the known functions of FRG1HP is its role in the regulation of cell adhesion, which is critical for the development and maintenance of tissues and organs.FRG1HP has been shown to play a role in the regulation of cell-cell adhesion, which is essential for the development and maintenance of tissues such as neural circuits, epithelial barriers, and blood vessels.

FRG1HP has also been shown to be involved in the regulation of cell migration and invasion, which are critical for the development and progression of many diseases, including cancer.FRG1HP has been shown to play a role in the regulation of cell migration and invasion by controlling the expression of genes involved in cell adhesion and cytoskeletal organization.

FRG1HP as a biomarker

FRG1HP has also been identified as a potential biomarker for various diseases. For example, FRG1HP has been shown to be expressed in various types of cancer, including breast, lung, and colorectal cancer.FRG1HP has also been shown to be involved in the regulation of cell signaling pathways, which are critical for the development and progression of many diseases.

FRG1HP has been shown to play a role in the regulation of cell adhesion and cytoskeletal organization, which are critical for the development and progression of many diseases, including cancer.FRG1HP has also been shown to be involved in the regulation of cell migration and invasion, which are critical for the development and progression of many diseases, including cancer.

Conclusion

FRG1HP is a gene that has been identified as a potential drug target and biomarker. Its involvement in various cellular processes that are associated with disease makes it an attractive target for drug development.FRG1HP has been shown to play a role in the regulation of cell adhesion, migration, and invasion, which are critical for the development and progression of many diseases.FRG1HP has also been shown to be a potential biomarker for various diseases, including cancer. Further research is needed to fully understand the potential of FRG1HP as a drug target and biomarker.

Protein Name: FSHD Region Gene 1 Family Member H, Pseudogene

The "FRG1HP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FRG1HP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets